Everyone everywhere could only dream of a customer like this
Calling Aurinia Pharmaceuticals one happy customer of Philadelphia clinical trial analytics provider Prevail InfoWorks is a gross understatement.
As right-to-try laws gain wider adoption, is stronger federal legislation needed?
The renewed interest in compassionate use — which first emerged as a national issue during the AIDS crisis of the 1980s — also has spurred pharmaceutical companies to ramp up “expanded access” programs.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
FDA greenlights Sarepta Therapeutics’ milestone treatment for Duchenne muscular dystrophy
Exondys 51 doesn’t cure Duchenne muscular dystrophy and will only help a minority of patients.
MyTomorrows is expanding to the U.S. and bringing its recipe for patient access to clinical trial drugs
MyTomorrows has had its greatest success in Europe, but is looking forward to bringing its services to the U.S.
This is how the presidential election is shaping the ongoing drug price debate
Drug prices are rising again and consumers, faced with higher out-of-pocket costs, are turning to lawmakers for help.
Pharmacy disruptor PillPack has raised another $30.1M following expansion
Only last year PillPack raised $50 million from investors such as Charles River Ventures, Menlo Ventures and Sherpa Ventures alongside Accel Partners and Atlas Venture
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Beyond the pill: 5 ways to create value with patient-centric services
In an outcomes-driven environment, focusing on patients is key but value needs to be demonstrated for all stakeholders when adopting new strategies to go beyond the pill.
3 healthcare sectors that are grabbing the eye of private equity investors
We find the most value in niche companies that can perform one particular service better than anyone else.
These companies paid the most to docs last year
Open payments data shows that Novartis shelled out the most to physicians in 2015 - a total of $540 million. Who followed the drugmaker?
Microbiota, novel antibiotics, and of course drug pricing among #BIO2016 takeaways
Drug pricing was destined to be a major topic, as manufacturers and payers continue to duke it out.
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Morning Read: Sanofi makes $9.3B offer for Medivation, Alere says it rejected Abbott’s request to scrap M&A deal
Also, Color Genomics expands its genetic test portfolio and Apple rolls out first clinical apps developed with CareKit.
Pharma companies, McKinsey highlight social media wins, insights
Some examples of how pharma companies are using social media to boost the drug industry's 1 percent industrial annual growth rate.
Morning Read: Report tracks steep drug price increases by pharma companies
Also, an outbreak of VIP syndrome at hospitals, fashionable prosthetics and Samsung's advancement of biosimilar drug for rheumatoid arthritis.
Morning Read: GSK’s new IP strategy seeks to reduce drug prices in low-income countries
Also, European Union regulators OK Bio Products Laboratory’s treatment for factor X deficiency and a fake press release for Pfizer fools The Washington Post and attracts ire from the big pharma company.
Valeant drug price increase coincides with Calif. Aid-in-Dying legislation
Elizabeth Wallner, diagnosed with Stage 4 colon cancer five years ago, has one word to describe the pharmaceutical executive who decided to double the price of Seconal: “Scumbag.”